Zacks Investment Research Lowers Leap Therapeutics (LPTX) to Hold

Leap Therapeutics (NASDAQ:LPTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Saturday, Zacks.com reports.

According to Zacks, “Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. “

LPTX opened at $1.47 on Friday. The company has a market capitalization of $33.74 million, a PE ratio of -0.59 and a beta of 2.23. Leap Therapeutics has a 12 month low of $1.35 and a 12 month high of $9.45.



Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.06). Sell-side analysts anticipate that Leap Therapeutics will post -1.52 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC boosted its stake in Leap Therapeutics by 63.3% in the first quarter. FMR LLC now owns 1,563,124 shares of the company’s stock valued at $2,923,000 after acquiring an additional 606,000 shares in the last quarter. BlackRock Inc. boosted its stake in Leap Therapeutics by 57.3% in the first quarter. BlackRock Inc. now owns 24,451 shares of the company’s stock valued at $45,000 after acquiring an additional 8,906 shares in the last quarter. Deutsche Bank AG boosted its stake in Leap Therapeutics by 45.7% in the fourth quarter. Deutsche Bank AG now owns 124,338 shares of the company’s stock valued at $248,000 after acquiring an additional 39,000 shares in the last quarter. Virtu Financial LLC acquired a new position in Leap Therapeutics in the fourth quarter valued at $28,000. Finally, Vanguard Group Inc boosted its stake in Leap Therapeutics by 23.2% in the third quarter. Vanguard Group Inc now owns 256,268 shares of the company’s stock valued at $1,997,000 after acquiring an additional 48,300 shares in the last quarter. 8.26% of the stock is owned by institutional investors and hedge funds.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Read More: What is intrinsic value?

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.